AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.
You may also be interested in...
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat.
Though the policy environment can be 'uncertain,' AstraZeneca has 'good grasp' on how the anemia drug for patients with chronic kidney disease will be covered under the Medicare end-stage renal disease bundled payment system, senior VP for market access Rick Suarez says.